Search clinical trials for: trospium chloride inhalation powder (TrIP)

Total 266 results

Endo Pharmaceuticals
Alkermes, Inc.

Completed

Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
AlgiPharma AS
Imperial College London; Cystic Fibrosis Foundation; University Hospital of Cologne and other collaborators

Withdrawn

A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis (SMR3372)

Cystic Fibrosis

Germany
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

Asthma | Chronic Obstructive Pulmonary Disease COPD

United States
Mannkind Corporation

Completed

A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males

Diabetes Mellitus, Type 2 | Healthy Males

Netherlands
Novartis Pharmaceuticals

Completed

Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)

Cystic Fibrosis

Spain, Germany, Switzerland, United Kingdom, Ireland
Mannkind Corporation

Completed

Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different Suppliers

Healthy Volunteers

United States
GlaxoSmithKline

Completed

Long-term Safety Study for GSK573719/GW642444 in Japanese (DB2115362)

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Romania, Russian Federation, Ukraine, Argentina, Poland, Czechia
GlaxoSmithKline

Completed

A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Russian Federation, Chile, Poland, Mexico, Estonia, Korea, Republic of, Philippines
Mannkind Corporation

Completed

A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Netherlands
GlaxoSmithKline

Completed

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Asthma

United States, Germany, Japan, Romania, Russian Federation, Poland
University of North Carolina, Chapel Hill
American Urogynecologic Society

Completed

The Effect of Anticholinergics on Cognitive Function in the Elderly (ACE)

Urinary Bladder, Overactive | Cognitive Function | Mental Competency

United States
Savara Inc.

Completed

AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

Cystic Fibrosis | MRSA

United States, Canada
Mannkind Corporation

No longer available

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

Type 1 Diabetes | Type 2 Diabetes

United States
GlaxoSmithKline

Completed

Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Asthma

United States, Germany, Japan, Romania, Ukraine, Poland
Savara Inc.
Cystic Fibrosis Foundation; Synteract, Inc.

Completed

Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

Cystic Fibrosis

United States
Allergan

Completed

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

Overactive Bladder

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Germany, Estonia, Chile, Netherlands, Peru, South Africa, Sweden, Mexico, United Kingdom, Italy, Philippines, Canada
Allergan

Completed

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial

Overactive Bladder | Pharmacokinetics | Elderly

United States
GlaxoSmithKline

Completed

A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Australia, Argentina, Germany, Spain, South Africa, Mexico, Peru, Netherlands, Canada, United Kingdom, Denmark, Chile, Italy, Sweden
Mannkind Corporation

Terminated

Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Chiesi Farmaceutici S.p.A.

Completed

Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® Device

COPD

Belgium
Allergan

Completed

Trospium Chloride XR in Obese Female Patients With Overactive Bladder

Obesity | Overactive Bladder | Incontinence

United States
Mannkind Corporation

Completed

Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function

Diabetes Mellitus | Mild Nephropathy | Moderate Nephropathy

United States
Mannkind Corporation

Completed

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

Diabetes Mellitus: Type 1

United States
Riphah International University

Completed

Effects of Power Ball on Grip Strength in Children With Developmental Delay.

Developmental Delay

Pakistan
Karuna Therapeutics

Terminated

An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia (PENNANT)

Schizophrenia

United States
GlaxoSmithKline

Completed

GSK573719 IV Enabling Study

Pulmonary Disease, Chronic Obstructive

United Kingdom
Hebrew SeniorLife

Not yet recruiting

ABSORB (Amount of Blueberries So Older Adults Reap Benefits)

Aging | Depressive Symptoms
Karuna Therapeutics

Completed

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)

Schizophrenia | Schizophrenia; Psychosis

United States, Ukraine
Mannkind Corporation

Completed

Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

Pulmonary Arterial Hypertension

United States
Karuna Therapeutics

Enrolling by invitation

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Schizophrenia

United States, Bulgaria, Serbia
Karuna Therapeutics

Completed

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

Schizophrenia

United States, Ukraine
Karuna Therapeutics

Active, not recruiting

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

Schizophrenia

United States
Neutec Ar-Ge San ve Tic A.Ş

Completed

Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment

COPD

Turkey
Karuna Therapeutics

Recruiting

A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE)

Schizophrenia

United States, Bulgaria, Serbia
Karuna Therapeutics

Completed

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)

Schizophrenia | Schizophrenia; Psychosis

United States
Respira Therapeutics, Inc.

Completed

A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Australia
McMaster University
Hamilton Health Sciences Corporation

Completed

Fluids in Sepsis and Septic Shock (FISSH)

Sepsis | Septic Shock

Canada
The University of Texas Medical Branch, Galveston
National Institute on Aging (NIA)

Recruiting

Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls

Urinary Bladder, Overactive | Urinary Incontinence | Accidental Falls

United States
Mansoura University
Amiri Hospital

Suspended

Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms:

Quality of Life | Ureter Obstruction | Ureter Stone

Egypt
Mannkind Corporation

Completed

A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere® Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL)

Healthy Subjects

United States
Becky Clarkson
National Institute on Aging (NIA)

Recruiting

Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence

Urgency Urinary Incontinence

United States
Karuna Therapeutics
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia (UNITE-001)

Schizophrenia

China
Allergan

Completed

Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects

Healthy

United States
Taris Biomedical LLC

Completed

Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder

Idiopathic Overactive Bladder With Urinary Incontinence

United States
Respira Therapeutics, Inc.

Completed

A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234

Healthy Volunteer

Australia
Allergan

Completed

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial

Overactive Bladder

United States
Karuna Therapeutics

Completed

A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-1)

Schizophrenia

United States
Taris Biomedical LLC

Completed

Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury

Neurogenic Detrusor Overactivity

United States

3

Subscribe